{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:43Z","timestamp":1792686103290,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.thromres.2024.01.012","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T02:21:20Z","timestamp":1705976480000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Anticoagulation in cancer patients with atrial fibrillation and grade 3\u20134 thrombocytopenia"],"prefix":"10.1016","volume":"235","author":[{"given":"Genady","family":"Drozdinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Spectre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Livneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Poran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.01.012_bb0005","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"European Heart Rhythm Association","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.01.012_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2024.01.012_bb0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.01.012_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clml.2015.10.001","article-title":"Atrial fibrillation in hematologic malignancies, especially after autologous hematopoietic stem cell transplantation: review of risk factors, current management, and future directions","volume":"16","author":"Mathur","year":"2016","journal-title":"Clin. Lymph. Myel. Leuk."},{"key":"10.1016\/j.thromres.2024.01.012_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","article-title":"Risk of malignant cancer among women with new-onset atrial fibrillation","volume":"1","author":"Conen","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.thromres.2024.01.012_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.01.012_bb0035","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.01.012_bb0040","doi-asserted-by":"crossref","unstructured":"A. Leader, C.N. Mendelson, S. Afek, R. Jaschek, A. Frajman, B.Z.O. Itzhaki, P. Raanani, M. Lishner, G. Spectre, Arterial thromboembolism in patients with atrial fibrillation and CHA2DS2-VASc score 0 to 2 with and without cancer, JACC 0 (n.d.). doi:https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.014.","DOI":"10.1016\/j.jaccao.2022.08.014"},{"key":"10.1016\/j.thromres.2024.01.012_bb0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.01.012_bb0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2024.01.012_bb0055","first-page":"oa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","author":"Raskob","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.01.012_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-021-02393-8","article-title":"Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy","author":"Livneh","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.01.012_bb0065","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia: venous thromboembolism in thrombocytopenic patient","volume":"91","author":"Khanal","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2024.01.012_bb0070","first-page":"112","article-title":"Safety of anticoagulation in patients with atrial fibrillation and MDS\/AML complicated by thrombocytopenia: an unresolved challenge: can they be managed? A report of three cases and literature review","author":"Caro","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2024.01.012_bb0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.01.012_bb0080","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2024.01.012_bb0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.01.012_bb0090","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1182\/bloodadvances.2023011235","article-title":"Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation","volume":"7","author":"Iyengar","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.01.012_bb0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4081\/oncol.2019.413","article-title":"Thrombocytopenia in solid tumors: prognostic significance","volume":"13","author":"Ghanavat","year":"2019","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.thromres.2024.01.012_bb0100","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1080\/10428194.2017.1306644","article-title":"Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort","volume":"58","author":"Houghton","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.thromres.2024.01.012_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann. Hematol."},{"issue":"2022","key":"10.1016\/j.thromres.2024.01.012_bb0110","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.01.012_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FJC.0000000000000607","article-title":"Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia","volume":"72","author":"Janion-Sadowska","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2021","key":"10.1016\/j.thromres.2024.01.012_bb0120","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.thromres.2024.01.012_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"HemaSphere"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:52:52Z","timestamp":1758736372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"alternative-id":["S0049384824000124"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.01.012","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in cancer patients with atrial fibrillation and grade 3\u20134 thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}